Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
MALAKOFF, France, September 16, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive treatment of varicose veins using High-Intensity Focused Ultrasound (HIFU), today reports its results for the first half ended 30 June 2026, approved by the Board of Directors on 15 September 2026, ahead of the FDA decision on the De Novo submission for Sonovein®, expected between the end of the third quarter and th
MALAKOFF, France, August 20, 2026--Regulatory News: Theraclion (Paris:ALTHE):
MALAKOFF, France, July 23, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026.
MALAKOFF, France, July 15, 2026--Regulatory News: Theraclion (Paris:ALTHE):
MALAKOFF, France, July 09, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect.
MALAKOFF, France, June 18, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that Mr. Yann Duchesne has decided not to stand for re-election as Director and Chairman of the Board following the General Meeting held on June 18, 2026, positions he had held since January 24, 2022.
MALAKOFF, France, June 08, 2026--Regulatory News: Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins (the "Company"), today announced that the American Medical Association (AMA) CPT Editorial Panel has approved the creation of a new Category III CPT code for non-invasive (HIFU) treatment of varicose veins, performed using Sonovein®. The new code wil
MALAKOFF, France, June 04, 2026--Regulatory News: THERACLION (ISIN: FR0010120402 – Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins, announces a significant milestone in its China expansion strategy with the deployment of a SONOVEIN® system at Boao Super Hospital in Hainan Province supported by its Joint Venture with its strategic partner Inner Mongolia Furui Medical Scie
MALAKOFF, France, June 01, 2026--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601718811/en/
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.